Response Lipoprotein Subclass Profiling Reveals Pleiotropy in the Genetic Variants of Lipid Risk Factors for Coronary Heart Disease: A Note on Mendelian Randomization Studies by Varbo, Anette et al.
Correspondence JACC Vol. 62, No. 20, 2013
November 12, 2013:1906–13
1908of Clinical Chemistry, Fimlab Laboratories, University of
Tampere, Tampere, Finland; {Department of Clinical Physiology,
University of Tampere and Tampere University Hospital,
Tampere, Finland; #Department of Medicine, University of Turku
and Turku University Hospital, Turku, Finland; **Research Centre
of Applied and Preventive Cardiovascular Medicine, University of
Turku, Turku, Finland; yyDepartment of Clinical Physiology and
Nuclear Medicine, Turku University Hospital, Turku, Finland;
zzDepartment of Epidemiology and Biostatistics, MRC-HPA
Centre for Environment and Health, School of Public Health,
Imperial College London, London, United Kingdom;
xxDepartment of Children and Young People and Families,
National Institute for Health and Welfare, Oulu, Finland;
kkInstitute of Health Sciences and Biocenter Oulu, University of
Oulu, Oulu, Finland; {{Oulu University Hospital, Oulu, Finland;
##Medical Research Council Centre for Causal Analyses in
Translational Epidemiology, University of Bristol, Bristol, United
Kingdom; and ***Computational Medicine, School of Social and
Community Medicine, University of Bristol, Bristol, United
Kingdom.
Please note: This study was supported by the Academy of Finland and the Strategic
Research Funding from the University of Oulu, Finland. The authors have reported
that they have no relationships relevant to the contents of this paper to disclose.
REFERENCES
1. Davey Smith G, Ebrahim S. Mendelian randomisation: can genetic
epidemiology contribute to understanding environmental determinants
of disease? Int J Epidemiol 2003;32:1–22.
2. Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Smith R,
Nordestgaard BG. Remnant cholesterol as a causal risk factor for
ischemic heart disease. J Am Coll Cardiol 2013;61:427–36.
3. Jørgensen AB, Frikke-Schmidt R, West AS, Grande P,
Nordestgaard BG, Tybjærg-Hansen A. Genetically elevated non-fasting
triglycerides and calculated remnant cholesterol as causal risk factors for
myocardial infarction. Eur Heart J 2013;34:1826–33.
4. Tukiainen T, Kettunen J, Kangas AJ, et al. Detailed metabolic and
genetic characterization reveals new associations for 30 known lipid loci.
Hum Mol Genet 2012;21:1444–55.
5. Niemi J, Mäkinen VP, Heikkonen J, et al. Estimation of VLDL, IDL,
LDL, HDL2, apoA-I, and apoB from the Friedewald inputsdapoB
and IDL, but not LDL, are associated with mortality in type 1 diabetes.
Ann Med 2009;41:451–61.ResponseLipoprotein Subclass Proﬁling Reveals
Pleiotropy in the Genetic Variants of Lipid
Risk Factors for Coronary Heart Disease
A Note on Mendelian Randomization StudiesWe thank Würtz and colleagues for their positive comments on our
recent paper (1) on remnant cholesterol (remnant-C) as a causal
risk factor for ischemic heart disease. We naturally agree that
lipoprotein metabolism is very complex, with many subclasses of
lipoproteins and different lipid contents of these subclasses, making
it difﬁcult, if not impossible, to ﬁnd genetic instruments completely
without pleiotropic effects on the other lipoprotein subclasses. The
various lipoprotein subclasses derived from the endogenous
pathway are a continuum from large very-low-density lipoproteinsexcreted from the liver, which are then degraded into intermediate-
density lipoproteins by lipolysis and exchange of lipids and apoli-
poproteins in plasma, which are then degraded further into
low-density lipoproteins. The differentiation into these speciﬁc
subclasses is somewhat arbitrarily deﬁned from the early ultracen-
trifugation studies (2). Therefore, it seems unlikely that there are
genetic variants that exclusively affect levels of just 1 lipoprotein
subclass. In our study (1), we used combinations of genetic variants
to minimize pleiotropy but of course did not completely avoid it;
this limitation was also discussed in our paper and nicely demon-
strated by Würtz and colleagues in their letter. Although the allele
score of TRIB1 (tribbles homolog-1), GCKR (glucokinase regula-
tory protein), and APOA5 (apolipoprotein A-V) genetic variants
used in our study as an instrument for nonfasting remnant-C alone
also had small effects on the cholesterol content in the other
lipoprotein subclasses, it was clearly associated with a much larger
effect on nonfasting remnant-C levels as demonstrated in our
Figure 4. This ﬁnding makes it unlikely that our results should be
explained by pleiotropic effects only.
Würtz and colleagues have performed an elegant lipoprotein
subclass proﬁling study by using nuclear magnetic resonance
(NMR) spectroscopy in 10,547 fasting samples from young adults
from the general population of Finland. This method is undoubt-
edly more detailed in differentiating between subclasses of lipo-
proteins and their lipid content than our simple calculation of
nonfasting remnant-C as nonfasting total cholesterol minus low-
density lipoprotein cholesterol minus high-density lipoprotein
cholesterol; however, it is exactly the simplicity of our calculation
that makes it clinically useful. Clinicians anywhere can use our
method to estimate levels of nonfasting remnant-C in patients
if they have measured a standard nonfasting lipid proﬁle and,
importantly, at no extra cost; lipoprotein subclass proﬁling with
NMR spectroscopy, even though it is very informative, is not
suitable for clinical purposes, because of the expenses and require-
ments of very specialized equipment, and not least because of the
complicated interpretation of the results.
In our study (1), we included adults aged 20 to >100 years who
were nonfasting at the time of blood sampling. This segment of
the population has a broader range and is closer to the everyday
state of the entire population (including with respect to other risk
factors for ischemic heart disease) than the fasting adolescent and
young adult segment examined by Würtz and colleagues; this
choice of patient population may have inﬂuenced the generaliz-
ability of their results. Thus, although they demonstrated pleiotropy
of the genetic instruments used by us, they probably did not
illustrate the entire variation of lipoprotein subclass proﬁles as
a function of these genetic variants. It is entirely possible that even
more pleiotropy could be detected if samples taken at different
times after a meal were analyzed, and if, for example, samples were
analyzed separately for men and women, young and old. Even more
complications can be added if one also considers the inﬂuence of
remnant-C on other processes likely in the biological pathway;
these include from elevated remnant-C to atherosclerosis to ischemic
heart disease (i.e., as with inﬂammation caused by elevated remnant-
C and not by elevated low-density lipoprotein cholesterol) (3).
After lowering of low-density lipoprotein cholesterol to recom-
mended levels, there is still a substantial residual risk of ischemic
heart disease. Some of this risk is probably explained by elevated
levels of cholesterol in the other lipoprotein subclasses than low-
density lipoprotein (i.e., remnant-C levels). It is therefore impor-
tant that clinicians acknowledge and intervene on these other lipid
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our simple way of estimating levels of nonfasting remnant-C makes
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1298–309.The Addition of Niacin to Statin
Therapy Improves High-Density
Lipoprotein Cholesterol Levels
But Not Metrics of Functionality
To the Editor: The role of niacin in the era of widespread statin use
has been called into question by 2 recent clinical trials, AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome
With Low HDL/High Triglycerides: Impact on Global Health)
and HPS2-THRIVE (Treatment of HDL to Reduce the Inci-
dence of Vascular Events), indicating no added beneﬁt when niacin
was added to standard low-density lipoprotein (LDL) reduction
therapy with simvastatin and ezetimibe (1).
Mass-based assessment of high-density lipoprotein cholesterol
(HDL-C) levels may not fully capture substantial variability in
HDL functional properties. Cholesterol efﬂux capacity, a marker of
the ability of HDL to accept cholesterol from macrophages and
thus facilitate reverse cholesterol transport, served as a stronger
predictor of atherosclerotic burden than HDL-C levels in 2 inde-
pendent cohorts (2). This inverse association with coronary disease
prevalence was conﬁrmed using a related assay in 2 additional
cohorts by Li et al. (3); an unexpected direct association with
prospective events awaits further conﬁrmation. Furthermore, the
HDL inﬂammatory index, a surrogate for HDL’s antioxidant
capacity, was impaired in patients in the midst of an acute coronary
syndrome (4).
We conducted a study designed to assess the impact of niacin
added to statin therapy onHDL-C levels, cholesterol efﬂux capacity,
and the HDL inﬂammatory index. Samples were derived from
a previously described randomized controlled trial (NCT00307307)
(5). In brief, patients with carotid atherosclerosis were randomized
to simvastatin 20 mg daily plus either placebo or extended-release
(ER) niacin, titrated up to 2 g daily. HDL-C levels and func-
tional parameters were assessed at baseline and after 6 months of
therapy.
Cholesterol efﬂux capacity was quantiﬁed using a previously
validated cell-based assay that quantiﬁes the ability of apolipopro-
tein B–depleted plasma to accept radiolabeled cholesterol from
J774 macrophages ex vivo (3). Similarly, the HDL inﬂammatory
index measured the capacity of apolipoprotein B–depleted plasma
to inhibit the oxidation of puriﬁed LDL-C (4). All assays were
performed in duplicate. To control for interassay variation, sample
values were normalized to a pooled plasma control run on each
plate.
The association between HDL functional parameters and
baseline biomarkers was assessed using Pearson correlation coefﬁ-
cients. Paired Student t tests were used to analyze the effect
of pharmacotherapy on HDL parameters. These changes were
compared with placebo using an analysis of covariance test using
the patient’s baseline value and treatment group as covariates.
Baseline and 6-month plasma samples were available in 39
patients, 19 in the simvastatin plus ER niacin group and 20 who
received simvastatin plus placebo. Fifteen of the 19 patients (79%)
randomized to receive ER niacin achieved the target dose of 2 g
daily, with a mean achieved daily dose of 1.8 g. Baseline charac-
teristics were similar to those of the study population as a whole and
revealed no signiﬁcant difference between treatment groups.
The mean age of study participants was 71 years; 64% were male,
26% had diabetes, 69% had hypertension, 23% had a history of
coronary artery disease, and 67% were taking a statin at baseline.
Average total cholesterol was 185 mg/dl, with mean HDL-C
and LDL-C of 46 mg/dl and 116 mg/dl, respectively. Median
values for triglycerides and C-reactive protein were 135 mg/dl and
1.4 mg/l, respectively.
Substantial variation was noted across study participants in HDL
functional parameters. Mean normalized cholesterol efﬂux capacity
was 0.95, with a range of 0.57 to 1.54; average HDL inﬂammatory
index value was 1.15, with range of 0.70 to 2.81. The mean
